ClinicalTrials.gg
CompletedNCT05282940Updated Jun 2, 2022

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

A Phase 1 interventional study of Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug and Microgynon CD in Therapeutic Equivalency, sponsored by Laboratorios Andromaco S.A.. Completed at 1 site in India. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by Laboratorios Andromaco S.A. (part of Grünenthal GmbH) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study will investigate the bioavailability in women of 2 tablet formulations containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The study will be performed at a single site with 36 subjects. Participants will take 2 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.

Read the detailed description

The primary objective of the study is to investigate the relative bioavailability of Levonorgestrel and Ethinyl estradiol of 2 tablet formulations with Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg and to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:

  • Test Product: Product manufactured by Laboratorios Andrómaco S.A.
  • Reference Product: Microgynon [Trademark], product of Bayer AG, Brasil. The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters área under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to infinite (AUC0-∞), and maximum plasma concentration (Cmax) for total Levonorgestrel and Ethinyl estradiol will be determined. Participants will be confined in the study site for approximately 34 hours during each study period (for 10 hours pre-dosing and for 24 hours post dosing) during which pharmacokinetic (PK) blood samples will be obtained. 21 blood samples will be taken up to 24 hours after the administration in each period. Participants will return to the site to provide additional blood samples at 48 h, and 72 h postdose. The washout period between the two study periods will be at least 14 days. A validated LC-MS/MS bio-analytical method will be used for estimation of plasma levels of Ethinyl-estradiol and Levonorgestrel. The safety objective is to evaluate the tolerability of both formulations in women by collecting adverse events.
02

Conditions studied

  • Therapeutic Equivalency
03

In context

Lead sponsor

Laboratorios Andromaco S.A. is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy non-pregnant, non-breast feeding female literate volunteers of 18 to 45 years (both years inclusive) with of 18.50 - 29.99 Kg/m2 and weight > 50 Kg.
  2. Healthy volunteers as evaluated by medical history, vitals and general clinical examination.
  3. Normal or clinically insignificant biochemical, hematological, urine and serology parameters.
  4. Normal or clinically insignificant EC.
  5. Negative urine test for drugs of abuse, negative pregnancy test and do not plan to become pregnant during course of the study and for 03 months after completion of study.
  6. Volunteers who are willing to use acceptable methods of (barrier method/IUD/surgical) or abstinence, for the entire duration of the study and do not plan to be pregnant for at least 1 month after the last drug administration.
  7. Volunteers who can give written and communicate effectively.

Exclusion criteria

Exclusion Criteria:

  1. History of any major surgical procedure in the past 03 months.
  2. History of any cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric and hematological disorders.
  3. History of chronic alcoholism/ chronic smoking/ drug of abuse.
  4. Volunteers with known to Ethinyl-estradiol and Levonorgestrel or any of the .
  5. History of consumption of tobacco containing products within 48 hours prior to proposed time of dosing
  6. Volunteer who are positive for surface antigen, anti- antibody, treponemal antibodies and (HIV 1\&2) antibodies.
  7. Present or past history of intake of drugs or any prescription drug or over the counter (OTC) drugs within 14 days which potentially modify kinetics / dynamics of Ethinyl-estradiol and Levonorgestrel or any other medication judged to be clinically significant by the investigator.
  8. History of consumption of grapefruit and/or its products within 10 days prior to the start of study.
  9. Volunteer who had participated in any other clinical study or who had bled during the last 03 months before check-in.
  10. History of consumption of one or more of the below, 48 hours prior to dosing: Xanthine containing food or drinks such as cola, chocolate, coffee or tea, citrus fruits or items (lime, lemon and orange), alcohol and any other food/beverage known to have interactions as deemed by the investigator.
  11. Volunteers who are dysphagic
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Levonorgestrel and Ethinyl estradiol Test Product

    Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.

    Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug

  • Active comparator
    Levonorgestrel and Ethinyl estradiol Reference Product

    Participants will receive two tablets of the test marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.

    Drug: Microgynon CD

Interventions

  • DrugLevonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug

    Drug page: Levonorgestrel

    Investigational Medicinal Product

  • DrugMicrogynon CD

    Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug

06

What researchers measure

Primary outcomes

  1. Total Ethinyl estradiol: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)

    21 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  2. Total Levonorgestrel: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)

    21 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  3. Total Ethinyl estradiol: Maximum plasma concentration (Cmax)

    21 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  4. Total Levonorgestrel: Maximum plasma concentration (Cmax)

    21 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  5. Total Ethinyl estradiol: Time to achieve maximum plasma concentration (tmax)

    21 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  6. Total Levonorgestrel: Time to achieve maximum plasma concentration (tmax)

    21 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

07

Study locations

1 site
  • Azidus Laboratories Ltd.
    Chennai, Tamil Nadu 600048, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Mar 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2022
First posted
Mar 16, 2022
StartActual
Feb 26, 2022
Primary completionActual
Mar 15, 2022
CompletionActual
Apr 8, 2022
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05282940
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
Feb 26, 2022
Primary completion
Mar 15, 2022
Completion
Apr 8, 2022
Last update
Jun 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion